Eisai Co., Ltd.
Launch in Japan of REKENVY® Subcutaneous Formulation “REKENVY® Subcutaneous 250mg Pen” as a Treatment for Early Alzheimer’s Disease
REKENVY® Subcutaneous 250mg Pen launched in Japan. A self-administrable SC formulation delivered as two pens once weekly (total 500mg). The launch expands options beyond IV administration, enabling at-home or on-the-go self-administration and is expected to lower barriers to treatment initiation and continuation. Impact on FY March 2027 financial guidance is described as minimal.
Key Figures
- Launch of lecanemab subcutaneous 250mg pen
- Two pens once weekly (total 500mg) dosing
- Enables at-home administration (self-administration)
AI要約
Overview of New Drug Launch
Eisai Co., Ltd., co-developer with Biogen, has launched the subcutaneous formulation of the anti-amyloid beta protofibril antibody REKENVY, the REKENVY Subcutaneous 250mg Pen, in Japan. Administered as 500mg once weekly using an autoinjector format that allows for self-administration. In addition to in-clinic IV administration, at-home and on-the-go self-administration become available options. The launch is expected to improve convenience and flexibility of treatment and reduce the burden associated with initiation and continuation of therapy.
Safety, Indications and Market Outlook
Self-administration should be performed under a physician's supervision as a general principle. Appropriate assessment and training are required for its use. Lecanemab is an antibody targeting Aβ and protofibrils and has been approved in Japan for early AD. SC administration is suggested to provide efficacy comparable to IV administration, and the convenience of SC dosing is likely to reduce the outpatient burden for patients and caregivers. In the long term, efficiencies in the AD treatment pathway are expected.
Eisai Co., Ltd.
Company overview · Stock price · Financial data · All IR
